20 completed, 6 unknown, 5 terminated, 4 withdrawn. 38 Phase 2, 7 Phase 1, 5 Phase 3.
Follow Peripheral Neuropathy: new trials by email Literature Review of Peripheral Neuropathy trials Research Report on Peripheral Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer Desloratodine, Placebo - Breast Cancer, Peripheral Neuropathy | Phase 2 | Recruiting | Montefiore Medical Center | 116 | 2026-09-01 | 2026-08-26 |
| Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) Sacituzumab Tirumotecan, MMAE-based ADC, Sacituzumab Tirumotecan (Observational Cohort) - Bladder Cancer, Metastatic Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 75 | 2026-07-15 | 2026-06-23 |
| The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases | Phase 2 / Phase 3 | Not yet recruiting | Universitas Sebelas Maret | 34 | 2026-03-01 | 2026-03-16 |
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Evaluation of Hydroxychloroquine to Prevent CIPN Hydroxychloroquine - Breast Cancer, Gynecologic Cancer | Phase 2 | Withdrawn | University of Arizona | 2024-06-01 | 2024-03-08 | |
| Vit D and Peripheral Neuropathy in Taxane Naive Patients Vitamin D - Vitamin D Deficiency, Peripheral Neuropathy | Phase 2 | Unknown | Assiut University | 60 | 2023-07-01 | 2023-05-10 |
| Efficacy of Roflumilast in Prevention of Peripheral Neuropathy Roflumilast, Placebo - Peripheral Neuropathy | Phase 1 / Phase 2 | Unknown | Mansoura University | 60 | 2023-07-01 | 2023-06-01 |
| NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy Placebo, NBP Softgel Capsules - Breast Cancer, Peripheral Neuropathy | Phase 2 | Withdrawn | Conjupro Biotherapeutics, Inc. | 2023-06-30 | 2023-06-08 | |
| Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients Silymarin, Placebo - Breast Cancer, Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Tanta University | 56 | 2022-10-28 | 2022-10-26 |
| Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients Metformin, Placebo - Peripheral Neuropathy, Breast Cancer | Phase 2 | Completed | Mansoura University | 76 | 2022-04-12 | 2023-03-09 |
| Efficacy of Cilostazol in Prevention of Peripheral Neuropathy Cilostazol, Placebo - Peripheral Neuropathy, Breast Cancer | Phase 1 / Phase 2 | Completed | Mansoura University | 71 | 2022-03-28 | 2023-03-15 |
| "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" Pentoxifylline, Paclitaxel, Placebo - Breast Cancer Female, Peripheral Neuropathy | Phase 2 / Phase 3 | Completed | Ain Shams University | 66 | 2021-10-03 | 2024-01-23 |
| Study of Nicotine for Pain Associated With Chemotherapy-Induced Peripheral Neuropathy Nicotine Transdermal Patch - Neuropathy, Peripheral Neuropathy | Phase 2 | Terminated | Virginia Commonwealth University | 4 | 2020-07-31 | 2023-11-08 |
| A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy WST-057 (4% pirenzepine) Lose Dose 2mL, WST-057 (4% pirenzepine) High Dose 4mL, Placebo Low Dose - Peripheral Neuropathy, Painful Diabetic Neuropathy | Phase 2 | Completed | WinSanTor, Inc | 58 | 2019-10-15 | 2022-12-16 |
| Candesartan in Peripheral Neuropathy Candesartan, Usual care - Peripheral Neuropathy | Phase 2 | Terminated | University Hospital, Limoges | 9 | 2019-05-01 | 2021-11-15 |
| SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study MD1003 - Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Completed | MedDay Pharmaceuticals SA | 15 | 2016-12-05 | 2020-11-02 |
| Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Salsalate, PLACEBO - Type 1 Diabetes, Peripheral Neuropathy | Phase 2 / Phase 3 | Completed | University of Michigan | 61 | 2016-10-01 | 2025-05-16 |
| SINF: Peripheral Neuropathy in Cancer Survivors Acupuncture, Nerve Function Tests, Questionnaires - Peripheral Neuropathy | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-03-01 | 2016-03-08 | |
| Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy FOLFOX regimen, HD6610 Granule, HD6610 Granule placebo - Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Jiangsu Province Hospital of Traditional Chinese Medicine | 64 | 2015-08-01 | 2015-12-02 |
| Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain Lidocaine HCl, Normal saline - Postherpetic Neuralgia, Diabetic Polyneuropathy | Phase 2 | Unknown | Seoul National University Hospital | 44 | 2015-08-01 | 2015-11-05 |
Showing 20 of 38. Sign in to see all of them.
Peripheral Nervous System Diseases (38) · Breast Neoplasms (9) · Pain (7) · Neuralgia (4) · Diabetes Mellitus (3) · Diabetic Neuropathies (3) · Diabetes Mellitus, Type 1 (2) · Lymphoma (2) · Multiple Myeloma (2) · Neoplasms (2) · Neuralgia, Postherpetic (2) · Neurotoxicity Syndromes (2) · Acute Pain (1) · Burkitt Lymphoma (1) · Carcinoma, Transitional Cell (1)
Nervous System Diseases (38) · Neuromuscular Diseases (38) · Neoplasms (14) · Pathological Conditions, Signs and Symptoms (14) · Neoplasms by Site (12) · Neurologic Manifestations (12) · Signs and Symptoms (12) · Breast Diseases (9) · Immune System Diseases (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Endocrine System Diseases (5) · Nutritional and Metabolic Diseases (5) · Pain (5) · Autoimmune Diseases (4)
Acupuncture Therapy (2) · Duloxetine Hydrochloride (2) · Glutamine (2) · Thioctic Acid (2) · salicylsalicylic acid (2) · Biotin (1) · Calcium Gluconate (1) · Carnosine (1) · Cilostazol (1) · DLBS 1033 (1) · Dietary Supplements (1) · Ethosuximide (1) · Folfox protocol (1) · Hydroxychloroquine (1) · Injections (1)
Mansoura University (3) · Academic and Community Cancer Research United (2) · M.D. Anderson Cancer Center (2) · University of Michigan (2) · Virginia Commonwealth University (2) · Ain Shams University (1) · Assiut University (1) · Beth Faiman (1) · Cairo University (1) · Columbia University (1) · Conjupro Biotherapeutics, Inc. (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Felipe Melo Cruz (1) · Fudan University (1) · Georgetown University (1)
United States (17) · Egypt (5) · China (2) · France (2) · Brazil (1) · Canada (1) · Indonesia (1) · South Korea (1) · United Kingdom (1)
Charles Loprinzi (2) · Rodica Pop-Busui, MD, PhD (2) · Amr Shafik, Assoc. Prof (1) · Angela Hansen (1) · Auro del Giglio, phD (1) · Barth L Wilsey, MD (1) · Beth Faiman (1) · Bruce Berger, MD (1) · Charles Loprinzi, M.D. (1) · David B. Clifford, MD (1) · Frederic Sedel, MD (1) · Huo JieGe, M.D. (1) · Jeffrey A. Allen, MD (1)
PMID 23538593, PMID 23565581, PMID 24886772, PMID 29381569, PMID 37583905, PMID 37899433, PMID 39727210, PMID 41352124
2025 (1), M01RR000036 (1), P30CA015083 (1)